Purpose
to conduct a placebo-controlled proof-of-concept phase III trial of the safety and efficacy of TDF and FTC/TDF in reducing HIV acquisition among HIV-negative partners within heterosexual HIV-discordant couples
Grantee
Division
Global Health
Date
JULY 2007
Region served
AFRICA
Committed amount
$69,847,223
Grant topic
HIV
Duration (months)
114
Grantee location
Seattle, Washington, United States
Related work
More about our financials
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.